Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Subscribe To Our Newsletter & Stay Updated
